TY - JOUR
T1 - The landscape of targeted therapies in TNBC
AU - Vagia, Elena
AU - Mahalingam, Devalingam
AU - Cristofanilli, Massimo
N1 - Funding Information:
This research received no external funding.
PY - 2020/4
Y1 - 2020/4
N2 - Triple negative breast cancer (TNBC) constitutes the most aggressive molecular subtype among breast tumors. Despite progress on the underlying tumor biology, clinical outcomes for TNBC unfortunately remain poor. The median overall survival for patients with metastatic TNBC is approximately eighteen months. Chemotherapy is the mainstay of treatment while there is a growing body of evidence that targeted therapies may be on the horizon with poly-ADP-ribose polymerase (PARP) and immune check-point inhibitors already established in the treatment paradigm of TNBC. A large number of novel therapeutic agents are being evaluated for their efficacy in TNBC. As novel therapeutics are now incorporated into clinical practice, it is clear that tumor heterogeneity and clonal evolution can result to de novo or acquired treatment resistance. As precision medicine and next generation sequencing is part of cancer diagnostics, tailored treatment approaches based on the expression of molecular markers are currently being implemented in clinical practice and clinical trial design. The scope of this review is to highlight the most relevant current knowledge regarding underlying molecular profile of TNBC and its potential application in clinical practice.
AB - Triple negative breast cancer (TNBC) constitutes the most aggressive molecular subtype among breast tumors. Despite progress on the underlying tumor biology, clinical outcomes for TNBC unfortunately remain poor. The median overall survival for patients with metastatic TNBC is approximately eighteen months. Chemotherapy is the mainstay of treatment while there is a growing body of evidence that targeted therapies may be on the horizon with poly-ADP-ribose polymerase (PARP) and immune check-point inhibitors already established in the treatment paradigm of TNBC. A large number of novel therapeutic agents are being evaluated for their efficacy in TNBC. As novel therapeutics are now incorporated into clinical practice, it is clear that tumor heterogeneity and clonal evolution can result to de novo or acquired treatment resistance. As precision medicine and next generation sequencing is part of cancer diagnostics, tailored treatment approaches based on the expression of molecular markers are currently being implemented in clinical practice and clinical trial design. The scope of this review is to highlight the most relevant current knowledge regarding underlying molecular profile of TNBC and its potential application in clinical practice.
KW - DNA damage repair
KW - Molecular profiling
KW - Personalized medicine
KW - Targeted treatment
KW - Triple negative breast cancer
UR - http://www.scopus.com/inward/record.url?scp=85083778833&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083778833&partnerID=8YFLogxK
U2 - 10.3390/cancers12040916
DO - 10.3390/cancers12040916
M3 - Review article
AN - SCOPUS:85083778833
VL - 12
JO - Cancers
JF - Cancers
SN - 2072-6694
IS - 4
M1 - 916
ER -